Posts tagged “Quintiles”
Quintiles and the Duke Clinical Research Institute are very different providers of clinical trial services but pharma executives give both high marks. Learn what makes them stand out.
Another life science services firm in the Triangle, PRA International, may follow in the footsteps of a bigger rival - Quintiles - by offering stock in order to raise capital. Just two years ago, PRA was at the center of takeover rumors in the range of $1 billion.
Fresh off an IPO that produced $1 billion for investors and the company, Quintiles on Wednesday announced a drug development deal in which it will work with Germany-based Merck Serono. But this contract is much different from others in which Quintiles shared some of the financial risk for new drug development. WRALTechWire Insiders get the story beyond the press release.
Quintiles completes its IPO selling 27.2 million shares, including the overallotment sold by investors who took stakes in Quintiles when it was private. Read just how much they stand to gain from the additional sale.
Chairman and co-founder Dr. Dennis Gillings joins his company's executive management team for the ringing of the opening bell on the NYSE on Friday. Quintiles executed the biggest IPO in Triangle history on Thursday.
Dennis Gillings, who started Quintiles in a trailer more than 30 years ago, rings the opening bell on the New York Stock Exchange today to celebrate the giant's return to public markets. Stephen Wiehe, who led SciQuest through a similar private-to-public Odyssey, recalls the "humbling" ringing bell honor.
Following Quintiles initial public stock offering, Chief Operating Officer John Ratliff gave WRAL Tech Wire an interview from the New York Stock Exchange. Read what he has to say about the now public company.
Shares in the world's largest life science services company are expected to begin trading Thursday on the New York Stock Exchange with an opening price of $40.
Financial expert Bob Broda takes a look at Quintiles' updated IPO offering, the big payday for co-founder and Chairman Dennis Gillings, and whether the stock is appealing to investors. Does Gillings deserve the cash out? Is Quintiles a good "buy"?
Quintiles, the world's largest life science services company, is seeking more than $900 million through a stock offering. Find out the price per share and how many shares Chairman Dennis Gillings wants to sell.
When Quintiles goes public, founder and Chairman Dennis Gillings and the private equity firms who together own the vast majority of the company stand to gain $25 million straight away without even selling a single share of their Quintiles stock.
In the 16 months prior to filing for an initial public offering, Quintiles spent more than $280 million buying companies that bolstered the Durham clinical research organization's capabilities in clinical testing, genomics and drug commercialization.
Quintiles IPO rumors were brewing for months but if you're wondering why now is the right time for a filing, take a look at the financial performance of the Durham contract research organization's publicly-traded peers.
On Friday, Quintiles disclosed plans to become a public company again through a stock offering of an estimated $600 million. Finance expert Bob Broda, who leads an RTP firm focused on compliance issues with an emphasis on Sarbanes-Oxley, reviewed the Quintiles filing at the request of WRAL Tech Wire and offers his views on where Quintiles stands plus where it seems to be headed.
Quintiles, which went private in 2008, has selected three banks to handle a return to the public markets, sources tell Reuters.